Stay updated on Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial page
- Check5 days agoChange DetectedLung cancer is added as a related topic and MedlinePlus Genetics link appears; the site revision was updated from v3.4.2 to v3.4.3.SummaryDifference0.2%

- Check13 days agoChange DetectedRemoved the related topics links 'Lung Cancer' and 'MedlinePlus Genetics' from the page. These related topics are navigation aids and are not part of the study details.SummaryDifference0.2%

- Check20 days agoChange DetectedAdded Lung cancer and related topics: MedlinePlus Genetics to the page, providing disease context and a patient education resource related to the study.SummaryDifference0.2%

- Check34 days agoChange DetectedAdded Revision: v3.4.2 to the page footer. Removed the government funding lapse notice about site operating status.SummaryDifference0.5%

- Check41 days agoChange DetectedNotice: A site-wide funding notice banner was added with a new revision tag (v3.4.1). The related topics 'Lung cancer' and 'MedlinePlus Genetics' were removed.SummaryDifference0.6%

- Check48 days agoChange DetectedUI and metadata updates were made: a glossary display option and new related topics (Lung cancer, MedlinePlus Genetics) were added. The revision indicator was updated to v3.4.0 with related QC metadata changes.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial page.